Clinical trials: Decompensated Liver Cirrhosis
Cirrhosis
Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease.
- Trial name
- NCT07652203
- Testing
- conventional therapy, propranolol
- Where
- China
- Volunteers
- 466 people
- Sponsor
- General Hospital of Shenyang Military Region
Alcoholic Cirrhosis
Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells
The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study…
- Trial name
- NCT05155657
- Testing
- Conventional therapy plus low dose UCMSCs treatment, Conventional therapy plus medium dose UCMSCs treatment, Conventional therapy plus high dose UCMSCs treatment
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Yantai Yuhuangding Hospital
Hepatitis B, Hepatitis C
A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis
Cirrhosis is a diffuse lesion characterized by architectural distortion of the liver because of collagen deposition and development of nodules of regenerating hepatocytes.
- Conditions
- Hepatitis B, Hepatitis C, Liver Cirrhosis
- Trial name
- NCT00562783
- Testing
- Vitaliver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hospital Authority, Hong Kong
Liver Cirrhosis, Decompensated Cirrhosis of Liver
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the…
- Trial name
- PROSPECT (NCT06855056)
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 189 people
- Sponsor
- European Foundation for Study of Chronic Liver Failure
Liver Cirrhosis
Observational Prospective Study.at the End of the Study the Patients Will be Classified According to PH,Serum Bicarbonate and Serum Sodium Into 6 Groups and Statistical Analysis Will be Performed Using Spss
1-to identify the prognostic value of serum bicarbonate and serum electrolytes at time of admission and their association with development of complications ,length of hospital stay ,prognosis and mortality in hospitalized…
- Trial name
- NCT05082064
- Testing
- arterial blood gases and serum electrolytes
- Where
- Egypt
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Sohag University
Decompensated Cirrhosis
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis.
- Trial name
- NCT06134544
- Testing
- Isomaltooligosaccharides (IMO)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis
Fecal Microbiota Transplantation in Decompensated Cirrhosis
Cirrhosis of the liver is the culmination point of long-standing chronic liver disease hallmarked by the cardinal features of liver fibrosis and portal hypertension.
- Trial name
- NCT04842539
- Testing
- Fecal Microbiota Transplantation, Standard of care
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Acute Kidney Injury, Hepatorenal Syndrome
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with…
- Trial name
- NCT02049125
- Where
- 4 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- University of Sao Paulo
Decompensated Cirrhosis
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
Three sequential dose cohorts are predefined for single administration: Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), and Cohort 3 (4.0 × 10⁶ cells/kg).
- Trial name
- HCL001 (NCT07488546)
- Testing
- Cohort 1 (1.0 × 10⁶ cells/kg), Cohort 2 (2.0 × 10⁶ cells/kg), Cohort 3 (4.0 × 10⁶ cells/kg)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Huicun Medical Technology Co., Ltd.
Decompensated Cirrhosis
Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis
The purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) transplantation in patients with Decompensated Cirrhosis.
- Trial name
- NCT02786017
- Testing
- Conventional therapy, Injectable Collagen Scaffold + HUC-MSCs
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Sciences
Decompensated Liver Cirrhosis
A Study of ADR-001 in Patients With Liver Cirrhosis
This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with liver cirrhosis caused by Hepatitis C or…
- Trial name
- NCT03254758
- Testing
- Mesenchymal stem cell
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
- Trial name
- NCT04512833
- Testing
- Cyberknife stereotactic body radiation therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Decompensated Hepatitis B Cirrhosis
Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis
Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis…
- Trial name
- HBV-DC (NCT07413549)
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Beijing Tuohua Weiye Biotechnology Co., Ltd.
Decompensated Cirrhosis, Cirrhotic Cardiomyopathy
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections.
- Conditions
- Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction
- Trial name
- CIRROSTAT (NCT06431919)
- Testing
- Simvastatin 20mg, Carvedilol 3.125 mg
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh